908 Devices Inc. (NASDAQ:MASS) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in 908 Devices Inc. (NASDAQ:MASS) by 1.2% in the 3rd quarter, Holdings Channel reports. The firm owned 567,788 shares of the company’s stock after purchasing an additional 6,634 shares during the quarter. Geode Capital Management LLC’s holdings in 908 Devices were worth $1,970,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in MASS. SG Americas Securities LLC acquired a new stake in 908 Devices in the third quarter valued at $36,000. Drive Wealth Management LLC purchased a new stake in shares of 908 Devices in the 3rd quarter worth about $50,000. Townsquare Capital LLC acquired a new stake in 908 Devices in the 3rd quarter valued at about $50,000. 49 Wealth Management LLC increased its holdings in 908 Devices by 16.2% during the 3rd quarter. 49 Wealth Management LLC now owns 31,099 shares of the company’s stock valued at $108,000 after acquiring an additional 4,343 shares in the last quarter. Finally, Barclays PLC raised its position in 908 Devices by 452.7% during the third quarter. Barclays PLC now owns 46,214 shares of the company’s stock worth $160,000 after acquiring an additional 37,853 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.

908 Devices Stock Down 5.2 %

MASS opened at $2.02 on Thursday. The firm’s 50 day moving average is $2.51 and its 200-day moving average is $3.63. 908 Devices Inc. has a 52-week low of $1.81 and a 52-week high of $8.87. The firm has a market capitalization of $70.34 million, a P/E ratio of -1.14 and a beta of 0.96.

Analyst Ratings Changes

MASS has been the topic of a number of analyst reports. Leerink Partnrs cut 908 Devices from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 13th. Stifel Nicolaus decreased their price objective on 908 Devices from $17.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Finally, Leerink Partners reiterated a “market perform” rating and set a $4.00 price objective (down previously from $12.00) on shares of 908 Devices in a research report on Wednesday, November 13th.

908 Devices Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.